Retatrutide: the research, read honestly
A triple-hormone weight-loss medication in late-stage trials, and the reason this site exists. It is not FDA-approved and cannot legally be prescribed today — so instead of a sales pitch, here is what the published research actually shows, and a waitlist for the day that changes.
Investigational (Eli Lilly LY3437943) · triple GIP/GLP-1/glucagon receptor agonist, once-weekly injection[1]
What treatment actually looks like
Nobody outside a clinical trial is legitimately taking retatrutide today — Lilly states plainly that it is available only to trial participants, and anything sold under that name outside a trial is unregulated and untested. What CAN be read today is the research: a completed phase 2 trial published in the New England Journal of Medicine, and phase 3 results Lilly has begun announcing. If it earns approval, treatment would look structurally like the approved weekly injectables — a low starting dose stepped up over weeks, under a provider's supervision.
How the dose builds
There is no approved dosing label. In the phase 2 trial, the highest-dose group started at 2 mg weekly and escalated every four weeks, reaching the 12 mg target by week 12 — a faster ramp to full dose than the approved GLP-1 medications, though the exact intermediate steps shown here are an illustrative rendering of the published protocol. Whatever dosing an approval eventually specifies is what a provider would follow.[1]
Doses step up gradually so the body can adjust — moving up is never automatic. A provider confirms each step based on how treatment is going, and slower schedules are common when side effects need more time to settle.
Medication level and measured weight change, together
The teal line models how a weekly injection with a roughly six-day half-life accumulates across the phase 2 trial's 48 weeks, following the trial's escalation to 12 mg. The green line is the trial's measured average: 17.5% below baseline by week 24 and 24.2% by week 48 — with the average still falling when the trial ended.[1]
Teal line: an illustrative pharmacokinetic model of once-weekly Retatrutide following the trialdose-escalation schedule (relative units — the shape, not a measurement). Green line: mean body-weight change reported in the phase 2 trial (12 mg arm, n=62, of 338 randomized). Weeks 24 and 48 are the trial's published table values; other points are approximate readings from the published weekly figure. Retatrutide is investigational -- these are research results, not an approved treatment's track record. Study means describe study populations — individual results vary, and treatment decisions belong to you and a licensed provider.
What the research measured
The phase 2 trial randomized 338 adults with obesity (no diabetes) across doses. At 48 weeks the 12 mg group averaged a 24.2% reduction, with the average still declining when the trial ended — and every participant in the 8 mg and 12 mg groups lost at least 5% of body weight. Lilly has since reported phase 3 results (TRIUMPH-1): an average 28.3% reduction over 80 weeks at 12 mg. Phase 3 data beyond the company's announcement have not yet been published in full.[1][2]
Side effects, honestly
- In phase 2, gastrointestinal side effects were the most common — nausea, diarrhea, vomiting, constipation — occurring primarily during dose escalation, more often at higher doses, and partially mitigated by the lower 2 mg starting dose.
- Gastrointestinal side effects were also the most common reason participants discontinued treatment; this is a drug still being characterized, which is what phase 3 exists to finish.
- Dose-dependent heart-rate increases were observed, peaking around week 24 and declining thereafter.
- Because it is unapproved, there is no FDA label, no standardized safety monitoring outside trials, and no quality control on gray-market products claiming to be retatrutide.
Source: published trial safety data[1]. Not a complete list — a provider reviews your health history before any prescription.
Common questions
Can I get retatrutide now?
No — not legitimately. Lilly states it is available only to participants in its clinical trials. Products sold online as "retatrutide" are unregulated research chemicals with no verified identity, purity, or dose. Our waitlist exists so you hear the moment a licensed provider can actually prescribe it.
When might it be approved?
Phase 3 trials are underway and Lilly has begun announcing results, but no approval date exists and we won't speculate on one. We will only ever notify the waitlist about legitimate, provider-prescribed availability.
Is it really more effective than tirzepatide or semaglutide?
The published numbers are larger — 24.2% average at 48 weeks in phase 2, versus roughly 15-21% in the other drugs' pivotal trials — but these are different trials with different participants and lengths, so direct superiority claims await head-to-head data. Read the numbers as separate studies, not a ranking.
What makes it "triple-acting"?
It activates three metabolic hormone receptors — GLP-1 and GIP, like tirzepatide, plus the glucagon receptor, which is thought to add an energy-expenditure effect. Whether that mechanism story fully explains the results is a research question; the trial numbers stand on their own.
Want to know the moment it's available?
Join the waitlist and we'll reach out when a provider can actually prescribe it. One email, no spam.
References
- 1.Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. doi:10.1056/NEJMoa2301972. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- 2.Eli Lilly and Company. Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
This page is educational information, not medical advice, and reading it does not create a provider relationship. Whether any medication is appropriate for you is a decision for you and a licensed clinician who knows your health history. Study results describe study populations under trial conditions; individual results vary. If you experience concerning symptoms while on any medication, contact your clinician or seek urgent care.